ImmuPharma PLC (IMM) · 2026-09-15
ImmuPharma has published peer-reviewed preclinical research showing P140 reduced steatohepatitis and fibrosis in an established mouse model of advanced metabolic dysfunction-associated steatohepatitis. The findings add biological evidence beyond P140's original lupus setting, but remain preclinical.
ImmuPharma PLC (IMM) · 2026-09-15
ImmuPharma has filed an international patent application for its P140 precision medicine approach in autoimmune disease, covering identification and treatment of patients with the Type M immune profile. The application now enters international search and publication, while commercial partnering discussions continue towards a 2026 deal.
ImmuPharma plc (IMM) · 2026-08-10
ImmuPharma selected Kymos Group as bioanalytical contract research organisation for Kapiglucagon's nonclinical and Phase 1 work, alongside US regulatory pathway evaluation subject to FDA confirmation.
ImmuPharma PLC (IMM) · 2026-07-22
ImmuPharma PLC said Thermo Fisher has been selected for Kapiglucagon, marking an important Chemistry, Manufacturing and Controls milestone and supporting next-stage pharmaceutical development and IND-enabling preparation.
ImmuPharma plc (IMM) · 2026-06-25
ImmuPharma has named Bachem as API manufacturing partner for Kapiglucagon after a competitive tender. The appointment is a CMC milestone and could help the programme move towards IND submission and first-in-human studies.
ImmuPharma plc (IMM) · 2026-06-24
ImmuPharma highlighted early-stage University of Murcia research on P140 and a possible glioblastoma use. The company has followed the work since 2024 and says it supports its wider P140 programme.